← Leaderboards
Murray J Favus
University Of Chicago
$423,464
Attributed
$423,464
Total exposure
11
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1K · FY2005–07$2K$1.5K$1K$500$0
'05
'06
'07
Funding mix
By agency
NIH$423,464 · 11
By mechanism
P01$323,259 · 1
M01$100,205 · 10
Top collaborators
No co-investigators on record.
Most similar at University Of Chicago
Same institution · by research overlap
- John C Lieske$18,323,845
- Elaine M Worcester$4,228,333
- Yan Chun Li$8,799,908
- Frederic L Coe$5,132,551
- David A Bushinsky$646,518
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectBone DensityHuman Therapy EvaluationPostmenopauseAlendronateOsteoporosisOral AdministrationDrug Screening /EvaluationSkeletal Disorder ChemotherapyVitamin D ReceptorsMetabolism Disorder ChemotherapyHypercalciuriaFemaleParathyroid HormonesGastrointestinal Nutrient AbsorptionPathologic ProcessReceptor ExpressionNephrocalcinosis1,25 DihydroxycholecalciferolAgingLongitudinal Human StudyWomen'S HealthCalcium
Grant awards (30)
VITAMIN D RECEPTOR LEVELS$1,124
M01 · FY2007 · RR · contact PI
VITAMIN D RECEPTOR IN IDIOPATHIC HYPERCALCIURIA$744
M01 · FY2005 · RR
PATHOGENESIS OF HUMAN AND MURINE HYPERCALCIURIA$107,753
P01 · FY2002 · DK
EFFECT OF MK 217 ON BONE MASS IN OSTEOPENIC WOMEN$0
M01 · FY2002 · RR
RALIOXIFENE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS$0
M01 · FY2002 · RR
ALENDRONATE VERSUS CALCITONIN TREATMENT FOR OSTEOPOROSIS$0
M01 · FY2002 · RR
ORAL ALENDRONATE FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN$0
M01 · FY2002 · RR
ALENDRONATE DOSES FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN$0
M01 · FY2002 · RR
HORMONAL INTERACTIONS AND BONE REGULATION IN IDIOPATHIC HYPERCALCIURIA$0
M01 · FY2002 · RR
TRIAL OF ORAL CALCIMIMETIC AGENT AMG 073 IN HYPERPARATHY$0
M01 · FY2002 · RR
VITAMIN D RECEPTOR LEVELS IN PATIENTS WITH IDIOPATHIC HYPERCALCIURIA$0
M01 · FY2002 · RR
PATHOGENESIS OF HUMAN AND MURINE HYPERCALCIURIA$107,753
P01 · FY2001 · DK
PATHOGENESIS OF HUMAN AND MURINE HYPERCALCIURIA$107,753
P01 · FY2000 · DK
ORAL ALENDRONATE FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN$32,779
M01 · FY2000 · RR
ALENDRONATE DOSES FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN$32,779
M01 · FY2000 · RR
ANDROGENS IN DRY EYE SYNDROME$32,779
M01 · FY2000 · RR
VITAMIN D RECEPTOR LEVELS IN PATIENTS WITH IDIOPATHIC HYPERCALCIURIA$0
M01 · FY2000 · RR
EFFECT OF MK 217 ON BONE MASS IN OSTEOPENIC WOMEN$0
M01 · FY2000 · RR
RALIOXIFENE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS$0
M01 · FY2000 · RR
RALIOXIFENE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS$0
M01 · FY2000 · RR
ALENDRONATE VERSUS CALCITONIN TREATMENT FOR OSTEOPOROSIS$0
M01 · FY2000 · RR
ALENDRONATE VERSUS CALCITONIN TREATMENT FOR OSTEOPOROSIS$0
M01 · FY2000 · RR
ORAL ALENDRONATE FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN$0
M01 · FY2000 · RR
ALENDRONATE DOSES FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN$0
M01 · FY2000 · RR
HORMONAL INTERACTIONS AND BONE REGULATION IN IDIOPATHIC HYPERCALCIURIA$0
M01 · FY2000 · RR
HORMONAL INTERACTIONS AND BONE REGULATION IN IDIOPATHIC HYPERCALCIURIA$0
M01 · FY2000 · RR
TRIAL OF ORAL CALCIMIMETIC AGENT AMG 073 IN HYPERPARATHY$0
M01 · FY2000 · RR
TRIAL OF ORAL CALCIMIMETIC AGENT AMG 073 IN HYPERPARATHY$0
M01 · FY2000 · RR
EFFECT OF MK 217 ON BONE MASS IN OSTEOPENIC WOMEN$0
M01 · FY2000 · RR
VITAMIN D RECEPTOR LEVELS IN PATIENTS WITH IDIOPATHIC HYPERCALCIURIA$0
M01 · FY2000 · RR